{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:39:38Z","timestamp":1793479178590,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,4,18]],"date-time":"2009-04-18T00:00:00Z","timestamp":1240012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11523-009-0108-y","type":"journal-article","created":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T05:14:29Z","timestamp":1239945269000},"page":"143-147","source":"Crossref","is-referenced-by-count":60,"title":["Maximum tolerated dose: clinical endpoint for a bygone era?"],"prefix":"10.1007","volume":"4","author":[{"given":"Chris H.","family":"Takimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,18]]},"reference":[{"key":"108_CR1","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68:8643\u20138653","journal-title":"Cancer Res"},{"key":"108_CR2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1200\/JCO.1988.6.9.1365","volume":"6","author":"WM Hryniuk","year":"1988","unstructured":"Hryniuk WM (1988) More is better. J Clin Oncol 6:1365\u20131367","journal-title":"J Clin Oncol"},{"key":"108_CR3","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2003.05.099","volume":"21","author":"CH Takimoto","year":"2003","unstructured":"Takimoto CH, Rowinsky EK (2003) Dose-intense paclitaxel: deja vu all over again? J Clin Oncol 21:2810\u20132814","journal-title":"J Clin Oncol"},{"key":"108_CR4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM200004133421508","volume":"342","author":"ME Lippman","year":"2000","unstructured":"Lippman ME (2000) High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Eng J Med 342:1119\u20131120","journal-title":"N Eng J Med"},{"key":"108_CR5","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.17.6719","volume":"26","author":"IE Haines","year":"2008","unstructured":"Haines IE (2008) Dose selection in phase I studies: why we should always go for the most effective. J Clin Oncol 26:3650\u20133652 author reply 2\u20133","journal-title":"J Clin Oncol"},{"key":"108_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","volume":"91","author":"BJ Druker","year":"2004","unstructured":"Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91:1\u201330","journal-title":"Adv Cancer Res"},{"key":"108_CR7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djh182","volume":"96","author":"WR Parulekar","year":"2004","unstructured":"Parulekar WR, Eisenhauer EA (2004) Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Nat Cancer Inst 96:990\u2013997","journal-title":"J Nat Cancer Inst"},{"key":"108_CR8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.2007.13.5913","volume":"26","author":"RH El-Maraghi","year":"2008","unstructured":"El-Maraghi RH, Eisenhauer EA (2008) Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 26:1346\u20131354","journal-title":"J Clin Oncol"},{"key":"108_CR9","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1158\/1078-0432.CCR-04-2538","volume":"11","author":"A Dowlati","year":"2005","unstructured":"Dowlati A, Robertson K, Radivoyevitch T et al (2005) Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 11:7938\u20137944","journal-title":"Clin Cancer Res"},{"key":"108_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2125.2006.02713.x","volume":"62","author":"S Kummar","year":"2006","unstructured":"Kummar S, Gutierrez M, Doroshow JH, Murgo AJ (2006) Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharm 62:15\u201326","journal-title":"Br J Clin Pharm"},{"key":"108_CR11","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1158\/1078-0432.CCR-06-2860","volume":"13","author":"BH Goulart","year":"2007","unstructured":"Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA (2007) Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 13:6719\u20136726","journal-title":"Clin Cancer Res"},{"key":"108_CR12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1200\/JCO.2007.15.5192","volume":"26","author":"S Sleijfer","year":"2008","unstructured":"Sleijfer S, Wiemer E (2008) Dose selection in phase I studies: why we should always go for the top. J Clin Oncol 26:1576\u20131578","journal-title":"J Clin Oncol"},{"key":"108_CR13","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1158\/1078-0432.CCR-05-1387","volume":"11","author":"U Emmenegger","year":"2005","unstructured":"Emmenegger U, Kerbel RS (2005) A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs. Clin Cancer Res 11:7589\u20137592","journal-title":"Clin Cancer Res"},{"key":"108_CR14","first-page":"131","volume":"7","author":"S Kummar","year":"2007","unstructured":"Kummar S, Kinders R, Rubinstein L et al (2007) Compressing drug development timelines in oncology using phase '0' trials. Nature reviews 7:131\u2013139","journal-title":"Nature reviews"},{"key":"108_CR15","author":"CH Takimoto","year":"2008","unstructured":"Takimoto CH (2008) Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Cancer Chem Pharm . doi: 10.1007\/s00280-008-0789-4","journal-title":"Cancer Chem Pharm"},{"key":"108_CR16","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1158\/1078-0432.CCR-07-2133","volume":"13","author":"MJ Ratain","year":"2007","unstructured":"Ratain MJ, Glassman RH (2007) Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res 13:6545\u20136548","journal-title":"Clin Cancer Res"},{"key":"108_CR17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2174\/1381612033455279","volume":"9","author":"P Workman","year":"2003","unstructured":"Workman P (2003) How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Current Pharm Design 9:891\u2013902","journal-title":"Current Pharm Design"},{"key":"108_CR18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0065-230X(06)96008-4","volume":"96","author":"D Sarker","year":"2007","unstructured":"Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96:213\u2013268","journal-title":"Adv Cancer Res"},{"key":"108_CR19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1124\/dmd.107.019711","volume":"36","author":"S Yamazaki","year":"2008","unstructured":"Yamazaki S, Skaptason J, Romero D et al (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267\u20131274","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"108_CR20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejca.2008.10.029","volume":"45","author":"MJ Ratain","year":"2008","unstructured":"Ratain MJ, Sargent DJ (2008) Optimising the design of phase II oncology trials: The importance of randomisation. Eur J Cancer 45(2):275\u2013280","journal-title":"Eur J Cancer"},{"key":"108_CR21","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237\u20132246","journal-title":"J Clin Oncol"},{"key":"108_CR22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909\u2013918","journal-title":"J Clin Oncol"},{"key":"108_CR23","first-page":"131","volume":"2","author":"P Workman","year":"2003","unstructured":"Workman P (2003) Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Molecular Cancer Therapeutics 2:131\u2013138","journal-title":"Molecular Cancer Therapeutics"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-009-0108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-009-0108-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-009-0108-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:15:05Z","timestamp":1559391305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-009-0108-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,18]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1007\/s11523-009-0108-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,18]]}}}